Page 106 - 83_02

enzymes for the screening of hepatotoxicity:
identification of bioactivable drugs and the potential
mechanism of toxicity involved. Arch Toxicol. 2013;
87:1115-1127.
40. Gómez-Lechón MJ, Tolosa L, Donato MT. Upgrading
HepG2 cells with adenoviral vectors that encode drug-
metabolizing enzymes: application for drug
hepatotoxicity testing. Expert Opin Drug Metab
Toxicol. 2017;13:137-148.
41. Gómez-Lechón MJ, Tolosa L. Human hepatocytes
derived from pluripotent stem cells: promising cell
model for drug hepatotoxicity screening. Arch
Toxicol. 2016; 90:2049-2061.
42. Yu B, He ZY, You P, et al. Reprogramming fibroblasts
into bipotential hepatic stem cells by defined factors.
Cell Stem Cell. 2013;13:328-340.
43. Baxter MA, Rowe C, Alder J, et al. Generating hepatic
cell lineages from pluripotent stem cells for drug
toxicity screening. Stem Cell Res 2010; 5:4-22.
44. Takayama K, Kawabata K, Nagamoto Y, et al. 3D
spheroid culture of hESC/hiPSC-derived hepatocyte-
like cells for drug toxicity testing. Biomaterials 2013;
34:1781-1789.
45. Liu X, Huang J, Chen T, et al. Yamanaka factors
critically regulate the developmental signaling
network in mouse embryonic stem cells. Cell Res.
2008;18:1177-1189.
46. Medine CN, Lucendo-Villarin B, Storck C, et al.:
Developing high-fidelity hepatotoxicity models from
pluripotent stem cells. Stem Cells Transl Med 2013;
2:505-9.
47. Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly
efficient generation of human hepatocyte-like cells
from induced pluripotent stem cells. Hepatology 2010;
51:297-305.
48. Kondo Y, Iwao T, Nakamura K, et al. An efficient
method for differentiation of human induced
pluripotent stem cells into hepatocyte-like cells
retaining drug metabolizing activity. Drug Metab
Pharmacokinet 2014; 29:237-243
49. Gieseck RL, Hannan NR, Bort R, et al. Maturation of
induced pluripotent stem cell derived hepatocytes by
3D-culture. PLoS One 2014; 9:e86372.
50. Anson BD, Kolaja KL, Kamp TJ. Opportunities for use
of human iPS cells in predictive toxicology. Clin
Pharmacol Ther 2011; 89:754-758.
51. Burkard A, Dahn C, Heinz S, et al. Generation of
proliferating human hepatocytes using Upcyte(R)
technology: characterisation and applications in
induction and cytotoxicity assays. Xenobiotica 2012;
42:939-956.
52. Levy G, Bomze D, Heinz S, et al. Long-term culture
and expansion of primary human hepatocytes. Nat
Biotechnol. 2015; 33:1264-1271
53. Tolosa L, Gómez-Lechón MJ, López S, et al. Human
Upcyte Hepatocytes: Characterization of the Hepatic
266
María José Gómez-Lechón Moliner
Phenotype and Evaluation for Acute and Long-Term
Hepatotoxicity Routine Testing. Toxicol Sci. 2016a;
152:214-229.
54. Milosevic N, Schawalder H, Maier P. Kupffer cell-
mediated differential down-regulation of cytochrome
P450 metabolism in rat hepatocytes. Eur J Pharmacol
1999; 26:75–87.
55. Liguori MJ, Ditewig AC, Maddox JF, et al.
Comparison of TNFa to lipopolysaccharide as an
inflammagen to characterize the idiosyncratic
hepatotoxicity potential of drugs: Trovafloxacin as an
example. Int J Mol Sci. 2010; 11:4697-714.
56. Kostadinova R, Boess F, Applegate D, et al. A long-
term three dimensional liver co-culture system for
improved prediction of clinically relevant drug-
induced hepatotoxicity. Toxicol Appl Pharmacol
2013; 268:1-16.
57. Sarkar U, Rivera-Burgos D, Large EM, et al. (2015)
Metabolite profiling and pharmacokinetic evaluation
of hydrocortisone in a perfused three-dimensional
human liver bioreactor. Drug Metab Dispos
43(7):1091-1099
58. Ohno M, Motojima K, Okano T, et al. Up-regulation of
drug-metabolizing enzyme genes in layered co-culture
of a human liver cell line and endothelial cells. Tissue
Eng Part A 2008; 14:1861-1869.
59. Krause P, Saghatolislam F, Koenig S, Unthanet al.
Maintaining hepatocyte differentiation in vitro
through co-culture with hepatic stellate cells. In Vitro
Cell Dev Biol Anim 2009; 45:205-12.
60. De Kock J, Ceelen L, De Spiegelaere W, et al. Simple
and quick method for whole-liver decellularization: a
novel in vitro three-dimensional bioengineering tool?
Arch Toxicol 2011; 85:607-612.
61. Lin RZ, Chang HY. Recent advances in three-
dimensional multicellular spheroid culture for
biomedical research. Biotechnol J 2008; 3:1172-1184.
62. van Zijl F, Mikulits W. Hepatospheres: Three
dimensional cell cultures resemble physiological
conditions of the liver. World J Hepatol 2010; 2:1-7.
63. Ohkura T, Ohta K, Nagao T, Kusumoto K, Koeda A,
Ueda T, Jomura T, Ikeya T, Ozeki E, Wada K, Naitoh
K, Inoue Y, Takahashi N, Iwai H, Arakawa H,
Ogihara T. Evaluation of human hepatocytes cultured
by three-dimensional spheroid systems for drug
metabolism. Drug Metab Pharmacokinet.
2014;29:373-378.
64. Bell CC, Hendriks DF, Moro SM, et al.
Characterization of primary human hepatocyte
spheroids as a model system for drug-induced liver
injury, liver function and disease. Sci Rep 2016;
6:25187.
65. Mueller D, Heinzle E, Noor F. 3D Hepatic In Vitro
Models as Tools for Toxicity Studies. Current Tissue
Eng 2013; 2:78-89.
@Real Academia Nacional de Farmacia. Spain